• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种整合的多组学分析方法确定了非肌肉浸润性膀胱癌的预后分子亚型。

An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer.

机构信息

Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark.

Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.

出版信息

Nat Commun. 2021 Apr 16;12(1):2301. doi: 10.1038/s41467-021-22465-w.

DOI:10.1038/s41467-021-22465-w
PMID:33863885
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8052448/
Abstract

The molecular landscape in non-muscle-invasive bladder cancer (NMIBC) is characterized by large biological heterogeneity with variable clinical outcomes. Here, we perform an integrative multi-omics analysis of patients diagnosed with NMIBC (n = 834). Transcriptomic analysis identifies four classes (1, 2a, 2b and 3) reflecting tumor biology and disease aggressiveness. Both transcriptome-based subtyping and the level of chromosomal instability provide independent prognostic value beyond established prognostic clinicopathological parameters. High chromosomal instability, p53-pathway disruption and APOBEC-related mutations are significantly associated with transcriptomic class 2a and poor outcome. RNA-derived immune cell infiltration is associated with chromosomally unstable tumors and enriched in class 2b. Spatial proteomics analysis confirms the higher infiltration of class 2b tumors and demonstrates an association between higher immune cell infiltration and lower recurrence rates. Finally, the independent prognostic value of the transcriptomic classes is documented in 1228 validation samples using a single sample classification tool. The classifier provides a framework for biomarker discovery and for optimizing treatment and surveillance in next-generation clinical trials.

摘要

非肌肉浸润性膀胱癌(NMIBC)的分子特征是具有不同临床结局的大生物学异质性。在这里,我们对诊断为 NMIBC 的患者(n=834)进行了综合的多组学分析。转录组分析确定了反映肿瘤生物学和疾病侵袭性的四个类别(1、2a、2b 和 3)。基于转录组的亚分型和染色体不稳定性水平提供了独立的预后价值,超过了既定的预后临床病理参数。高染色体不稳定性、p53 通路破坏和 APOBEC 相关突变与转录组 2a 类和不良预后显著相关。RNA 衍生的免疫细胞浸润与染色体不稳定的肿瘤相关,并在 2b 类中富集。空间蛋白质组学分析证实了 2b 类肿瘤的更高浸润程度,并表明更高的免疫细胞浸润与更低的复发率之间存在关联。最后,使用单个样本分类工具在 1228 个验证样本中证明了转录组类别的独立预后价值。该分类器为生物标志物的发现以及在下一代临床试验中优化治疗和监测提供了框架。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fed1/8052448/b8a30413502a/41467_2021_22465_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fed1/8052448/bf6545a6bce4/41467_2021_22465_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fed1/8052448/fd2763d5bf22/41467_2021_22465_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fed1/8052448/1b2c9e95622e/41467_2021_22465_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fed1/8052448/74fe9e377af2/41467_2021_22465_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fed1/8052448/5ffdba699e59/41467_2021_22465_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fed1/8052448/b8a30413502a/41467_2021_22465_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fed1/8052448/bf6545a6bce4/41467_2021_22465_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fed1/8052448/fd2763d5bf22/41467_2021_22465_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fed1/8052448/1b2c9e95622e/41467_2021_22465_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fed1/8052448/74fe9e377af2/41467_2021_22465_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fed1/8052448/5ffdba699e59/41467_2021_22465_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fed1/8052448/b8a30413502a/41467_2021_22465_Fig6_HTML.jpg

相似文献

1
An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer.一种整合的多组学分析方法确定了非肌肉浸润性膀胱癌的预后分子亚型。
Nat Commun. 2021 Apr 16;12(1):2301. doi: 10.1038/s41467-021-22465-w.
2
Identification of an immune-related long non-coding RNA signature and nomogram as prognostic target for muscle-invasive bladder cancer.鉴定一种免疫相关的长非编码 RNA 特征,并构建列线图作为肌层浸润性膀胱癌的预后靶标。
Aging (Albany NY). 2020 Jun 24;12(12):12051-12073. doi: 10.18632/aging.103369.
3
Prognostic and clinicopathologic value of ki-67 and profilin 1 immunohistochemical expression in primary pT1 urothelial bladder cancer.Ki-67 和 Profilin 1 免疫组化表达在原发性 pT1 尿路上皮膀胱癌中的预后和临床病理价值。
J Cancer Res Ther. 2021 Apr-Jun;17(2):434-442. doi: 10.4103/jcrt.JCRT_408_19.
4
Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.高级别 T1 期与肌层浸润性膀胱癌中 PD-L1 的差异表达及其预后意义。
J Urol. 2017 Oct;198(4):817-823. doi: 10.1016/j.juro.2017.04.102. Epub 2017 May 6.
5
HMOX1 is an important prognostic indicator of nonmuscle invasive bladder cancer recurrence and progression.HMOX1 是预测非肌肉浸润性膀胱癌复发和进展的一个重要预后指标。
J Urol. 2011 Feb;185(2):701-5. doi: 10.1016/j.juro.2010.09.081. Epub 2010 Dec 18.
6
Bladder Tumor Subtype Commitment Occurs in Carcinoma Driven by Key Signaling Pathways Including ECM Remodeling.膀胱癌亚型的形成与关键信号通路有关,包括细胞外基质重塑,这些通路驱动了癌的发生。
Cancer Res. 2021 Mar 15;81(6):1552-1566. doi: 10.1158/0008-5472.CAN-20-2336. Epub 2021 Jan 20.
7
High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma.肿瘤细胞 PD-L1 高表达与预后不良相关,而免疫细胞 PD-L1 高表达则是膀胱癌的一个有利预后因素。
Future Oncol. 2021 Aug;17(22):2893-2905. doi: 10.2217/fon-2021-0092. Epub 2021 Jun 30.
8
Tumor expression of miR-34a-3p is an independent predictor of recurrence in non-muscle-invasive bladder cancer and promising additional factor to improve predictive value of EORTC nomogram.miR-34a-3p 在肿瘤中的表达是非肌层浸润性膀胱癌复发的独立预测因子,有望成为提高 EORTC 列线图预测价值的附加因素。
Urol Oncol. 2019 Mar;37(3):184.e1-184.e7. doi: 10.1016/j.urolonc.2018.10.014. Epub 2018 Nov 13.
9
Overexpression of replication protein A3 is associated with unfavorable outcome in bladder urothelial carcinoma.复制蛋白 A3 的过表达与膀胱尿路上皮癌的不良预后相关。
J Cancer Res Ther. 2021 Jul;17(3):771-776. doi: 10.4103/jcrt.jcrt_275_21.
10
Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.对于新诊断的非肌层浸润性膀胱癌,单次广泛经尿道切除术后联合适当的膀胱内灌注治疗的肿瘤学结局。
Int Urol Nephrol. 2015 Sep;47(9):1509-14. doi: 10.1007/s11255-015-1048-3. Epub 2015 Jul 7.

引用本文的文献

1
Expression of PD-1 and PD-L1 in BCG-treated NMIBC.卡介苗治疗的非肌层浸润性膀胱癌中PD-1和PD-L1的表达
Bladder Cancer. 2025 Aug 17;11(3):23523735251368683. doi: 10.1177/23523735251368683. eCollection 2025 Jul-Sep.
2
Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy.癌症诱导的神经损伤促进对抗PD-1疗法的耐药性。
Nature. 2025 Aug 20. doi: 10.1038/s41586-025-09370-8.
3
A Double-Humanized Murine Model in Bladder Cancer: A Novel Preclinical Model for Cancer Immunology Research.一种膀胱癌双人源化小鼠模型:癌症免疫学研究的新型临床前模型。

本文引用的文献

1
Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis.通过综合多组学分析,研究肌肉浸润性膀胱癌中顺铂化疗反应的分子相关性。
Nat Commun. 2020 Sep 25;11(1):4858. doi: 10.1038/s41467-020-18640-0.
2
Identification of Differential Tumor Subtypes of T1 Bladder Cancer.T1 膀胱癌的肿瘤亚型鉴别。
Eur Urol. 2020 Oct;78(4):533-537. doi: 10.1016/j.eururo.2020.06.048. Epub 2020 Jul 17.
3
Identification of an immunotherapy-responsive molecular subtype of bladder cancer.
Cancer Med. 2025 Aug;14(15):e71150. doi: 10.1002/cam4.71150.
4
A technical review of multi-omics data integration methods: from classical statistical to deep generative approaches.多组学数据整合方法的技术综述:从经典统计方法到深度生成方法
Brief Bioinform. 2025 Jul 2;26(4). doi: 10.1093/bib/bbaf355.
5
Machine Learning and Experimental Validation Reveal MYH11 as a Novel Prognostic Biomarker and Therapeutic Target in Bladder Cancer.机器学习与实验验证揭示MYH11是膀胱癌新的预后生物标志物和治疗靶点。
J Inflamm Res. 2025 Jun 25;18:8357-8387. doi: 10.2147/JIR.S519719. eCollection 2025.
6
Retinoic acid metabolism related gene CYP26B1 promotes tumor stemness and tumor microenvironment remodeling in bladder cancer.维甲酸代谢相关基因CYP26B1促进膀胱癌的肿瘤干性和肿瘤微环境重塑。
J Cancer. 2025 Apr 22;16(8):2476-2491. doi: 10.7150/jca.101406. eCollection 2025.
7
Pathway-based cancer transcriptome deciphers a high-resolution intrinsic heterogeneity within bladder cancer classification.基于通路的癌症转录组解析膀胱癌分类中的高分辨率内在异质性。
J Transl Med. 2025 Jun 17;23(1):666. doi: 10.1186/s12967-025-06682-1.
8
Deciphering riddles in molecular subtyping of bladder cancer.解读膀胱癌分子亚型中的谜题。
Asian J Urol. 2025 Apr;12(2):217-231. doi: 10.1016/j.ajur.2024.09.006. Epub 2024 Dec 5.
9
Impact of concomitant carcinoma in situ distribution on non-muscle-invasive bladder cancer progression risk.原位癌分布情况对非肌层浸润性膀胱癌进展风险的影响。
BJU Int. 2025 Aug;136(2):236-244. doi: 10.1111/bju.16793. Epub 2025 May 26.
10
Molecular feature-based classification of retroperitoneal liposarcoma: a prospective cohort study.基于分子特征的腹膜后脂肪肉瘤分类:一项前瞻性队列研究。
Elife. 2025 May 23;14:RP100887. doi: 10.7554/eLife.100887.
鉴定膀胱癌免疫治疗反应的分子亚型。
EBioMedicine. 2019 Dec;50:238-245. doi: 10.1016/j.ebiom.2019.10.058. Epub 2019 Nov 15.
4
Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials.非肌肉浸润性膀胱癌膀胱内卡介苗免疫抵抗的适应性:对前瞻性卡介苗无反应试验的影响。
Clin Cancer Res. 2020 Feb 15;26(4):882-891. doi: 10.1158/1078-0432.CCR-19-1920. Epub 2019 Nov 11.
5
Molecular changes during progression from nonmuscle invasive to advanced urothelial carcinoma.从非肌肉浸润性到高级尿路上皮癌的进展过程中的分子变化。
Int J Cancer. 2020 May 1;146(9):2636-2647. doi: 10.1002/ijc.32737. Epub 2019 Nov 14.
6
A Consensus Molecular Classification of Muscle-invasive Bladder Cancer.肌肉浸润性膀胱癌的共识分子分类。
Eur Urol. 2020 Apr;77(4):420-433. doi: 10.1016/j.eururo.2019.09.006. Epub 2019 Sep 26.
7
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.欧洲泌尿外科学会非肌肉浸润性膀胱癌(TaT1 和原位癌)指南 - 2019 年更新版。
Eur Urol. 2019 Nov;76(5):639-657. doi: 10.1016/j.eururo.2019.08.016. Epub 2019 Aug 20.
8
The androgen receptor regulates a druggable translational regulon in advanced prostate cancer.雄激素受体调控晚期前列腺癌中可药物治疗的翻译调控网络。
Sci Transl Med. 2019 Jul 31;11(503). doi: 10.1126/scitranslmed.aaw4993.
9
Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling.上尿路尿路上皮癌具有管腔-乳头 T 细胞耗竭的结构和激活的 FGFR3 信号通路。
Nat Commun. 2019 Jul 5;10(1):2977. doi: 10.1038/s41467-019-10873-y.
10
Molecular pathology of the luminal class of urothelial tumors.尿路上皮肿瘤 luminal 型的分子病理学。
J Pathol. 2019 Nov;249(3):308-318. doi: 10.1002/path.5318. Epub 2019 Aug 27.